Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The lack of vaccines against several important viral diseases necessitates the development of therapeutics to save lives and control epidemics. In recent years, therapeutic antibodies have received considerable attention due to their good safety profiles and clinical success when used against viruses such as respiratory syncytial virus, Ebola virus and Hendra virus. The binding affinity of these antibodies can directly impact their therapeutic efficacy. However, we and others have also demonstrated that the subtype of Fc-gamma receptors (FcγRs) engaged influences the stoichiometric requirement for virus neutralization. Hence, the development of therapeutic antibodies against infectious diseases should consider the FcγRs engaged and Fc-effector functions involved. This review highlights the current state of knowledge about FcγRs and FcγR effector functions involved in virus neutralization, with emphasis on factors that can affect FcγR engagement. A better understanding of Fc-FcγR interactions during virus neutralization will allow development of therapeutic antibodies that are efficacious and can be administered with minimal side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 2×
“FcgRIIA and FcgRIIIA, on the other hand, bind strongly to immune complexes but not to monomeric IgG [17] .”
BackgroundCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“, IL-1b, TNFa, IL-6 and IL-8) due to immune complexes can result in immunogenicity-related adverse events [78].”
BackgroundCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“For instance, the Phase I trial of the antiCD28 mAb TGN1412 resulted in immune-mediated cytokine storm and multiorgan failure in healthy volunteers, highlighting the importance of assessing the likelihood of such adverse events [79].”
BackgroundFilipe, V., Hawe, A., & Jiskoot, W. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0073-2 · Cited by 1,885 · cited 2×
“Filipe V, Hawe A, Jiskoot W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates.”
BackgroundShields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“These observations were correlated with in vitro ADCC analysis where peripheral blood mononuclear cells obtained from FcgRIIA H/H and/or FcgRIIIA V/V genotype showed higher ADCC activity compared with those of other genotypes with lesser affinity to IgG [28].”
ResultBibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
SHP-1 regulates Fcγ receptor–mediated phagocytosis and the activation of RAC
Kant, A. M., De, P., Peng, X., Yi, T., Rawlings, D. J., Kim, J. S., & Durden, D. L. (2002) · Blood · doi:10.1182/blood.v100.5.1852.h81702001852_1852_1859 · Cited by 81
Cited by
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Van Vleet, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.008 · Cited by 286
Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation
Junker, F., Gordon, J., & Qureshi, O. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01393 · Cited by 219
Lucas, A. T., Moody, A., Schorzman, A. N., & Zamboni, W. C. (2021) · Antibodies · doi:10.3390/antib10030030 · Cited by 40
Metadata
- Authors
- Chan, K. R., Ong, E. Z., Mok, D. Z., & Ooi, E. E.
- Venue
- Expert Review of Anti-infective Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-08-24
- Volume
- 13
- Issue
- 11
- Pages
- 1351-1360
- ISSN
- 1478-7210 (ISSN-L)
- 1744-8336
- OpenAlex
- W2142498740
- Cited by
- 40
- References
- 10
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. https://app.cochat.ai/papers/10.1586/14787210.2015.1079127
- The paper
- Chan, K. R., Ong, E. Z., Mok, D. Z., & Ooi, E. E. (2015). Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Review of Anti-infective Therapy. https://doi.org/10.1586/14787210.2015.1079127
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.